Twist Bioscience CAO sells 4,961 shares at $56.88

Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported an open-market sale of Common Stock.

Rhea-AI Filing Summary

Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported an open-market sale of Common Stock. He sold 4,961 shares on May 8, 2026 at a price of $56.881 per share. After this transaction, he directly holds 49,674 shares of Twist Bioscience Common Stock.

Insights

Equity compensation and insider-trading analyst

Routine-sized open-market sale by Twist Bioscience CAO with sizable holdings remaining.

The Chief Accounting Officer, Robert F. Werner, executed an open-market sale of 4,961 shares of Twist Bioscience Common Stock at $56.881 per share. The transaction is coded as an open-market sale rather than option activity or tax withholding.

Following the sale, he directly holds 49,674 shares, indicating he retains a substantial equity position relative to the amount sold. The filing shows no derivative positions remaining in this snapshot and does not indicate any related gifts, tax withholding, or restructuring transactions.

The net effect in this report is a single net-sell transaction totaling 4,961 shares. Future company filings may provide additional context if there are further trades or new equity awards that change his overall exposure.

Insider Trade Summary

Net Seller: 4,961 shares

Net Sell 1 txn

Insider WERNER ROBERT F.

Role Chief Accounting Officer

Sold 4,961 shs ($282K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,961	$56.881	$282K

Holdings After Transaction: Common Stock — 49,674 shares (Direct)

Key Figures

Shares sold: 4,961 shares Sale price per share: $56.881 per share Shares owned after sale: 49,674 shares +1 more

4 metrics

Shares sold 4,961 shares Open-market sale of Common Stock on May 8, 2026

Sale price per share $56.881 per share Price for 4,961 shares sold

Shares owned after sale 49,674 shares Direct ownership following transaction

Net shares sold 4,961 shares Net-sell direction in transaction summary

Key Terms

open-market sale, Common Stock, Form 4, Chief Accounting Officer

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Chief Accounting Officer financial

"officer_title: "Chief Accounting Officer""

A chief accounting officer is a senior executive responsible for overseeing a company's financial records and ensuring all accounting practices are accurate and compliant with regulations. They play a key role in preparing financial reports that help investors understand the company's financial health, much like a trusted navigator guiding a ship through complex waters. Their work ensures transparency and trust in the company's financial information.

FAQ

What insider transaction did Twist Bioscience (TWST) report for Robert F. Werner?

Twist Bioscience reported that Chief Accounting Officer Robert F. Werner completed an open-market sale of Common Stock. He sold 4,961 shares on May 8, 2026 at a price of $56.881 per share, as disclosed in the Form 4 insider trading report.

How many Twist Bioscience (TWST) shares did the CAO sell and at what price?

The Chief Accounting Officer sold 4,961 shares of Twist Bioscience Common Stock. The reported sale price was $56.881 per share in an open-market transaction dated May 8, 2026, according to the Form 4 filing with the SEC.

How many Twist Bioscience (TWST) shares does Robert F. Werner hold after the sale?

After the reported transaction, Robert F. Werner directly owns 49,674 shares of Twist Bioscience Common Stock. This post-transaction holding is disclosed in the Form 4 and reflects his remaining direct ownership after selling 4,961 shares in the open market.

Was the Twist Bioscience (TWST) insider transaction an open-market sale or option exercise?

The transaction was an open-market sale of Common Stock, not an option exercise. The Form 4 lists transaction code “S” and describes it as an open-market or private sale, with no derivative securities or option conversion activity reported for this filing.

Did the Twist Bioscience (TWST) Form 4 include any derivative or tax-withholding transactions?

No, the Form 4 shows only one non-derivative transaction, an open-market sale of Common Stock. The derivative summary lists no remaining derivative positions, and the transactionSummary reports zero tax-withholding, gift, or restructuring share movements in this particular filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		S		4,961	D	$56.881	49,674	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)